NewAmsterdam Pharma Company N.V. (NAMS) stock analysis
NAMS · NewAmsterdam Pharma Company N.V.
Latest recorded price: USD 19.46
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: free cash flow margin -657.8%, ROIC -323.1%. The model flags 3 risk signals for this company (2 high severity).